As of Q4'25, Pfizer's latest reported gross margin stands at 69.97%, with an operating margin of 21.01% and a net profit margin of -9.39%. This indicates a strong gross and operating margin, but the company closed the period with a negative net profit margin. From Q1'23 to Q4'25, the chart reveals significant volatility in all three margin metrics. Gross margin remained robust throughout, generally ranging between 70% and 79%, except for a notable dip to 30% in Q3'23. Operating and net profit margins experienced sharper fluctuations, including negative values in late 2023 and Q4'25, reflecting periods of operational and net losses. Despite some recovery in 2024 and early 2025, the negative net profit margin at the end of 2025 suggests ongoing profitability challenges.